Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
IND.227
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
- NCT02784171 ↗
- Completed
- Canadian Cancer Trials Group
- Deep size, estimated: 301+ verified statements
We haven't built an HCP commentary report on IND.227 (untreated advanced pleural mesothelioma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IND.227 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 31 posts on X | |
| 9 podcast episodes | |
| 3 YouTube videos |
The trial
ClinicalTrials.gov- Official title
- A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
- Phase
- Phase 2/Phase 3
- Status
- Completed
- Conditions
- Mesothelioma
- Interventions
- Cisplatin; Pemetrexed; Pembrolizumab
- Arms
- Arm A - Cisplatin/Pemetrexed · Active comparator
- Arm B - Cisplatin/Pemetrexed/Pembrolizumab · Active comparator
- Arm C - Pembrolizumab (Phase II only) · Active comparator
- Enrollment
- 520
- Primary outcomes
- Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression
- Phase III: Overall Survival Defined as Time From Randomization to the Date of Death From Any Cause
- Sponsor
- Canadian Cancer Trials Group with National Cancer Institute, Naples, Merck Sharp & Dohme LLC, Intergroupe Francophone de Cancerologie Thoracique
- Start
- Nov 11, 2016
- Primary completion
- Oct 11, 2024
- Results posted
- Yes
- Registry record
- NCT02784171 · updated Dec 10, 2024
Publications
linked from the registry- Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023 Dec 16;402(10419):2295-2306. doi: 10.1016/S0140-6736(23)01613-6. Epub 2023 Nov 3. PubMed 37931632
- Uprety D. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma. Clin Lung Cancer. 2021 Mar;22(2):71-73. doi: 10.1016/j.cllc.2020.11.009. Epub 2020 Dec 2. No abstract available. PubMed 33358660